The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Live session held on February 11, 2026, from 2:00–2:30 PM CST with speaker Tara Graff presenting on “Implementing Bispecific Antibodies in Community Practice.”
In this video from SOHO Asia 2026, Dr. DiPersio discusses highlights from the acute myeloid leukemia session with Drs. Andrew Wei, Naval Daver, and Richard Dillon. Dr. DiPersio particularly focuses on how to use MRD to follow patients to make treatment decisions and
provides his own take on the topic.
In this video interview from SOHO Asia, Dr. Wang, MD, PhD, consultant hematologist at National Taiwan University Cancer Center, discusses the current unmet needs in MDS, MPN, and CMML and shares his perspective on the shift toward novel treatment options, the importance of bridging basic science with clinical practice, and his vision for future Asia-Pacific regional collaborations in the in hematology.
The US Food and Drug Administration (FDA) approved an update to the prescribing information for axicabtagene ciloleucel (Yescarta), removing the previous Limitations of Use for patients with relapsed or refractory primary central nervous system lymphoma (PCNSL).
John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis, Missouri, discusses the need for public-private partnerships to move novel therapies forward in the treatment of blood cancers. He also speaks about how cross-sector collaboration can create better research paths for the future.
To access the SOHO Career Center click the following link.
